Primary hepatoid adenocarcinoma of the lung: an observational study of six cases
Research Connections · 2026-11-10
DOI: 10.1093/rescon/vmag208 ↗Abstract
Abstract Background and Aims Hepatoid adenocarcinoma (HAC) is a rare extrahepatic malignancy characterized by hepatocellular differentiation. Pulmonary involvement is uncommon and may mimic metastatic hepatocellular carcinoma (HCC). We describe the clinicopathological and immunohistochemical features of six patients with hepatoid adenocarcinoma of the lung (HAL). Methods We retrospectively reviewed patients diagnosed with HAL at a tertiary university hospital between January 2021 and December 2025. Clinical, radiological, histopathological, immunohistochemical, molecular, treatment, and follow-up data were collected. Diagnosis was based on integrated clinicopathological findings and exclusion of metastatic HCC and extra-pulmonary hepatoid adenocarcinoma. Results Six male patients aged 47–70 years were identified, all with a history of chronic smoking. Dyspnoea was the most frequent presenting symptom. A pulmonary mass was identified on initial CT in five patients, whereas one patient presented with a femoral metastasis and the pulmonary lesion was subsequently detected by 18F-FDG PET scan. Four patients had distant metastases at diagnosis. Tumours predominantly showed solid, nested, or trabecular architecture with marked cytological atypia and mitotic activity. Hepatoid differentiation was identified in all cases. All tumours expressed CK7 and HepPar-1, while TTF-1 showed cytoplasmic staining. Serum AFP was normal in all three patients tested. A KRAS G12C mutation was identified in one patient, and PD-L1 TPS was 5% in two patients. Three patients died during follow-up. Conclusion HAL is a rare, aggressive neoplasm predominantly affecting male smokers. Accurate diagnosis requires integration of morphology, immunohistochemistry, and comprehensive clinical and radiological evaluation to exclude metastatic HCC and extra-pulmonary hepatoid adenocarcinoma.
EUVIMED